As a preview to Discovery on Target 2014, Cambridge Healthtech Institute’s Kip Harry speaks with Dr. Tamara Maes on recent advancements in LSD1 Inhibition, including the current status of Oryzon Genomics’ ORY-1001 trial, in collaboration with Roche. 

Dr. Tamara Maes will be discussing this in more depth at Discovery on Target’s Targeting Histone Methyltransferases and Demethylases Conference. Learn more at http://www.discoveryontarget.com/Histone-Methyltransferases


Discovery On Target 2014 | Development of Histone Demethylase Inhibitors

CHI interviews Drs. Trevor Perrior, Research Director at Domainex, and Gregg Siegel, CEO of ZoBio about the current challenges in developing novel chemical matter targeting HMTs and HDMs, novel tools and technologies enabling discovery, and emerging targets within this space.

Discussion questions include:
1.	How have you seen this field evolve over the past few years? 
2.	What are some of the challenges in developing novel chemical matter targeting these enzymes?
3.	What are some of the tools and technologies that are aiding epigenetic inhibitor discovery?
4.	What are some other interesting and emerging HMT or HDM targets? 
5.	You are giving a lecture during the upcoming Targeting Histone Methyltransferases and Demethylases meeting, part of Discovery on Target 2015 this September 23-24 in Boston. What do you hope to share with attendees during your lecture?

Find more information at http://www.DiscoveryOnTarget.com/

Discovery on Target 2105 | Histone Methyltransferase and Demethylase Inhibitor Discovery

Bonus Podcast for CHI's interview with Drs. Trevor Perrior, Research Director at Domainex, and Gregg Siegel, CEO of ZoBio

Listen to the full podcast here:
https://soundcloud.com/chi-podcasts/histone-methyltransferase-and-demethylase-inhibitor-discovery

Find more information about the conference here:
http://www.DiscoveryOnTarget.com/

Bonus Podcast: Histone Methyltransferase and Demethylase Inhibitor Discovery

CHI interviews Dr. Christopher Schofield, Head of Organic Chemistry in the Chemistry Research Laboratory at the University of Oxford, regarding his current work designing new demethylase inhibitors, current challenges, and his outlook for continued development in this space.

Discussion Questions Include:

How have you have seen this space evolve over the past few years? 
What are some demethylase targets currently being pursued by Medicinal Chemists?
Can you please describe some of the work currently being conducted in your lab toward the discovery of new demethylase inhibitors? 
What challenges have been encountered designing small molecule histone demethylase inhibitors? 
How do you see this research evolving over the next few years?

For more information, please visit http://www.DiscoveryOnTarget.com/Histone-Methyltransferases/

Discovery on Target 2016 | Advances and Challenges in Histone Demethylase Inhibitors

The CHI Podcasts are produced by the Cambridge Healthtech Institute and offer in-depth interviews with research and business leaders from many facets of biotechnology.